BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » research products

How to find unique market opportunities by stem cell type

May 15, 2017 By Cade Hildreth (CEO) Leave a Comment

Stem cell market opportunities

As the first and only market research firm to specialize in the stem cell industry, BioInformant’s 175-page global strategic report “Stem Cell Research Products – Opportunities, Tools, and Technologies” evaluates strategies across the stem cell product spectrum, with emphasis on opportunities for research product development.

It explores unique market opportunities by stem cell type, including mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), induced pluripotent stem cells (iPSCs), embryonic stem cells (ESCs), neural stem cells (NSCs), and more. [Read more…]

Filed Under: Stem Cells Tagged With: competitive analysis, market intelligence, research products, stem cells

Lonza Reports Strong First Quarter in History in Terms of Sales and Earnings

May 2, 2016 By Cade Hildreth (CEO) Leave a Comment

Lonza Reports Record First Quarter - Depositphotos_23783565_m-2015.jpg

The possibilities arising from stem cells have resulted in great commercial interest, with potential applications ranging from their use in the reversal of disease, to targeted cell therapy, tissue regeneration, pharmacological testing on cell-specific tissues, toxicology assessment, and more. To facilitate research resulting from interest in these potential far-ranging applications, a large and growing stem cells research products market has emerged.

One of several large companies selling stem cell research products is Lonza Group. Others competitors include Thermo Fisher Scientific, BD Biosciences, Merck KGaA, Miltenyi Biotec, STEMCELL Technologies, Clontech (a Takara Bio Company), GE Healthcare Life Sciences, and more.

In major news released today, Lonza Group from Basel, Switzerland, reported a record 1st quarter of 2016, recording its “strongest first quarter in history in terms of sales and earnings.”

Lonza has several different business divisions, including Pharma&Biotech, Specialty Ingredients, Custom Manufacturing, and more. One of these divisions is Lonza Bioscience (LBS), which develops and manufactures tools for life sciences researchers. In this April 26, 2016, press release, Lonza states: “Our healthy Bioscience Solutions business showed further improvement compared with the previous year, driven by product introductions and sound demand in all sub-segments.”

To learn more about Lonza’s role within the research products market, view “Stem Cell Research Products – Opportunities, Tools, and Technologies.

To learn more about Lonza’s record first quarter results, read the full press release issued by Lonza Group (below). [Read more…]

Filed Under: Press Releases, Stem Cells Tagged With: biotechnology, cell therapy, Lonza, research products, stem cells

BioInformant Releases “Stem Cell Research Products – Opportunities, Tools, & Technologies” with Market Size, Segments, Trends, & Projections to 2020

February 10, 2016 By Cade Hildreth (CEO) Leave a Comment

BioInformant Releases “Stem Cell Research Products, Opportunities, Tools, & Technologies - Market Size, Segments, Trends, and Projections to 2020”

February 11, 2016; Washington, DC — BioInformant announces the February 2016 release of its global strategic report, “Stem Cell Research Products, Opportunities, Tools, and Technologies” with market size, segments, trends, and projections to 2020.

The first and only market research firm to specialize in the stem cell industry, BioInformant has more than a decade of historical information on all segments of the stem cell market, by stem cell type. This powerful 175 page global strategic report contains market size, segments, trends, and projections through 2020, as well a social analytics and an end-user survey of nearly 300 stem cell scientists. The “Survey of Stem Cell Scientists” identifies technical requirements, unmet needs, and purchasing preferences of stem cell researchers worldwide. [Read more…]

Filed Under: Adipose SCs, HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: market report, press release, research products, stem cells, STEMCELL Technologies, Thermo Fisher Scientific

Imagine Increasing Revenue from Stem Cell Products and Decreasing Risk

February 10, 2016 By Cade Hildreth (CEO) Leave a Comment

Imagine Increasing Revenue from Stem Cell Products and Decreasing Risk

We have helped hundreds of the top companies increase revenue from stem cell products and decrease risk. The key is targeted market intelligence, because it will help you to approach institutional investors for fundraising rounds, guide internal decision-making within your company, and reduce the risk that has traditionally accompanied new product development. Simply put, it will help you make smarter decisions, faster.

Whether or not you can invest in the recently released global strategic report, “Stem Cell Research Products – Opportunities, Tools, and Technologies,” the following is an important introduction to the stem cell research products marketplace, including key trends and future projections. [Read more…]

Filed Under: Adipose SCs, HSCs, iPS Cells, MSCs, Neural Stem Cells, Stem Cells Tagged With: Accellta, Cellular Dynamics International, cynata, market report, research products, RoosterBio, stem cells

[Case Study] ReproCELL as an Early Competitor within the Induced Pluripotent Stem Cell (iPSC) Marketplace

December 9, 2015 By Cade Hildreth (CEO) Leave a Comment

ReproCELL as an Early Competitor within the Induced Pluripotent Stem Cell (iPSC) Marketplace

ReproCELL Enters iPSC Marketplace by 2009

In 2006, Shinya Yamanaka’s lab at Kyoto University in Japan created the first induced pluripotent stem cells (iPSCs) from mouse cells. By 2007, a series of follow-up experiments had been competed at Kyoto University in which human adult cells were transformed into iPSCs. Nearly simultaneously, a research group led by James Thomson at the University of Wisconsin-Madison accomplished the same feat of deriving iPSC lines from human somatic cells.

Just a couple years later in 2009, a forward-thinking company, ReproCELL, entered the iPSC marketplace. At that time, the scientific community was just beginning to explore the cell type, including how to derive, maintain, and differentiate iPSCs.

Established in 2003 as a venture company originating from the University of Tokyo and Kyoto University, ReproCELL was the first company to make induced pluripotent stem cell (iPSC) products commercially available with the launch of its human iPSC-derived cardiomyocytes, which it called “ReproCario.” Other stem cell derived cardiomyocytes are now available commercially from Cellular Dynamics International, GE Healthcare, Cellectis, and others.

ReproCELL’s Commercialization of Induced Pluripotent Stem Cell (iPSC) Products

ReproCELL’s innovation in the area of iPSC commercialization has been driven in part by joint research relationships it established in 2003 with Tokyo University and in 2004 with Kyoto University, the eventual site of iPSC discovery in 2006. Since 2009, ReproCELL has expanded its line of iPSC reagents and iPSC-derived cell lines to include heart, liver, and nerve cells.

The company primarily sells these products as research tools, although they also have the potential for use in toxicology and drug discovery applications. Currently, ReproCELL offers the following iPSC products:

  • Research reagents optimized for human iPSC culture
  • Human iPSC-derived cardiomyocytes, which launched in April of 2009 (the first iPSC product to be sold commercially)
  • Human iPSC-derived neurons, launched in October of 2010
  • Human iPSC-derived hepatocytes, launched in May of 2012
  • Disease model cell generation using human iPS cell technologies

ReproCELL Expands Through Strategic Acquisitions

To date, ReproCELL has furthered its dominance in the area of iPSC products through a series of strategic acquisitions, including acquisition of Reinnervate, BioServe Biotechnologies, and Stemgent, and all occurring in 2014. Over time, ReproCELL has acquired a growing selection of smaller companies, making strategic acquisitions one of its primary techniques for marketplace dominance and company growth.

Most recently, on November 24, 2015, ReproCELL announced that it would be expanding its drug discovery services through its acquisition of the firm Biopta. Based in Glasgow, UK, and Maryland, USA, the Biopta Group describes itself as “providing contract research services to the pharmaceutical industry since 2002 and has established itself as the world leader in the use of fresh functional human tissues to better predict drug activity prior to clinical trials.”

Click here to read the full press release about the event, titled “ReproCELL Acquires Biopta to Expand its Drug Discovery Services.”


To learn more about emerging trends and opportunities within stem cell markets, view our global strategic reports for the stem cell and cord blood industry.

Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report
Complete 2015-16 Induced Pluripotent Stem Cell (iPSC) Industry Report
The Market for Stem Cell Biobanking and Storage - Size, Segments, and Trends
The Market for Stem Cell Biobanking and Storage – Size, Segments, and Trends
Mesenchymal Stem Cells - Advances & Applications
Mesenchymal Stem Cells – Advances & Applications

 

 

 

 

 

 

Filed Under: iPS Cells, Stem Cells Tagged With: iPSC, market intelligence, market news, ReproCELL, research products, stem cells, strategy

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • U.S. Cord Blood Banking Survey Cord Blood Banking Survey of U.S. Parents [2017]
    Rated 0 out of 5
    $197
  • Exosome Companies 2020 Global Database of Exosome Companies
    Rated 0 out of 5
    $149 $97
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.